NCT04620603View on ClinicalTrials.gov

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

March 20, 2024

Study Completion Date

September 1, 2025

Conditions
Cutaneous Malignant MelanomaRenal Cell CancerUrothelial Cancer of Renal Pelvis
Interventions
RADIATION

Low Dose Rate Brachytherapy (LDR)

LDR on treatment day 1

DRUG

Standard-of-Care Immunotherapy

Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.

Trial Locations (1)

44122

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT04620603 - Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | Biotech Hunter | Biotech Hunter